| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.5 |
| mRNA | Bryostatin 1 | GDSC1000 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.5 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | CGP-082996 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.5 |
| mRNA | LFM-A13 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | NSC-207895 | GDSC1000 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.5 |